Arabic Arabic English English French French German German
dark

NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

NGM Biopharmaceuticals, Inc. today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other ligands. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Patient Interactive Systems Minimizes Nurse Burnout & Facilitates Patient Education

Next Post

Kelyniam Global Releases 2nd Quarter 2021 Financials Maintains Profitability – Covid Challenges Continue

Related Posts
Total
0
Share